Austin, Texas, United States, January 23rd, 2026, FinanceWire
- LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments
- Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile
- The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise
LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target.
LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (“PP2A”). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Contact
IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
